Rüdiger von Kummer
Dresden University of Technology
137 Papers
719 Citations
Rüdiger von Kummer is an academic researcher from Dresden University of Technology. The author has contributed to research in topics: Stroke & Medicine. The author has an hindex of 48, co-authored 131 publications. Previous affiliations of Rüdiger von Kummer include St George's Hospital.
Chat about Author
Papers
Thrombolysis with Alteplase 3 to 4.5 Hours After Acute Ischemic Stroke
Werner Hacke,Markku Kaste,Erich Bluhmki,Miroslav Brozman,Antoni Dávalos,Donata Guidetti,Vincent Larrue,Kennedy R. Lees,Zakaria Medeghri,Thomas Machnig,Dietmar Schneider,Rüdiger von Kummer,Nils Wahlgren,Danilo Toni +13 more
TL;DR: As compared with placebo, intravenous alteplase administered between 3 and 4.5 hours after the onset of symptoms significantly improved clinical outcomes in patients with acute ischemic stroke; altePlase was more frequently associated with symptomatic intracranial hemorrhage.
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
Werner Hacke,Markku Kaste,Cesare Fieschi,Rüdiger von Kummer,Antoni Dávalos,Dieter Meier,Vincent Larrue,Erich Bluhmki,Stephen M. Davis,Geoffrey A. Donnan,Dietmar Schneider,Exuperio Díez-Tejedor,Paul Trouillas +12 more
TL;DR: Despite the increased risk of intracranial haemorrhage, thrombolysis with alteplase at a dose of 0·9 mg/kg in selected patients may lead to a clinically relevant improvement in outcome.
3.4K
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials
Werner Hacke,Geoffrey A. Donnan,Cesare Fieschi,Markku Kaste,Rüdiger von Kummer,Joseph P. Broderick,Thomas G. Brott,Michael Frankel,James C. Grotta,E. Clarke Haley,Thomas Kwiatkowski,Steven R. Levine,Chris Lewandowski,Mei Lu,Patrick D. Lyden,John R. Marler,Suresh C. Patel,Barbara C. Tilley,Gregory W. Albers,Erich Bluhmki,Manfred Wilhelm,Scott Hamilton,Atlantis Trials Investigators,Ecass Trials Investigators +23 more
TL;DR: The sooner that rt-PA is given to stroke patients, the greater the benefit, especially if started within 90 min, which suggests a potential benefit beyond 3 h, but this potential might come with some risks.
2.7K
Guidelines for management of ischaemic stroke and transient ischaemic attack 2008
Peter A. Ringleb,Marie-Germaine Bousser,Gary A. Ford,Philip M.W. Bath,Michael Brainin,Valeria Caso,Álvaro Cervera,Ángel Chamorro,Charlotte Cordonnier,László Csiba,Antoni Dávalos,Hans-Christoph Diener,José M. Ferro,Werner Hacke,Michael G. Hennerici,Markku Kaste,Peter Langhorne,Kennedy R. Lees,Didier Leys,J. Lodder,Hugh S. Markus,Jean-Louis Mas,Heinrich Mattle,Keith W. Muir,Bo Norrving,Victor Obach,Stefano Paolucci,E. Bernd Ringelstein,Peter D. Schellinger,Juhani Sivenius,Skvortsova Vi,Katharina S. Sunnerhagen,Lars Thomassen,Danilo Toni,Rüdiger von Kummer,Nils Wahlgren,Marion F Walker,Joanna M. Wardlaw +37 more
TL;DR: The article covers referral and emergency management, Stroke Unit service, diagnostics, primary and secondary prevention, general stroke treatment, specific treatment including acute management, management of complications, and rehabilitation.
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.
Kennedy R. Lees,Erich Bluhmki,Rüdiger von Kummer,Thomas G. Brott,Danilo Toni,James C. Grotta,Gregory W. Albers,Markku Kaste,John R. Marler,Scott Hamilton,Barbara C. Tilley,Stephen M. Davis,Geoffrey A. Donnan,Werner Hacke +13 more
TL;DR: Patients with ischaemic stroke selected by clinical symptoms and CT benefit from intravenous alteplase when treated up to 4.5 h should be taken to shorten delay in initiation of treatment to increase benefit to a maximum.
2.2K